For the first time in over two decades, Cannabinoid Hyperemesis Syndrome has its own official diagnostic code. The WHO activated ICD-10 code R11.16 on October 1, 2025, and emergency departments are already taking notice.
"A person often will have multiple emergency department visits until it is correctly recognized."
UW Medicine Researchers- ▸The WHO added ICD-10 code R11.16 for Cannabis Hyperemesis Syndrome on October 1, 2025.
- ▸Emergency departments report steady increases in CHS visits over the past decade.
- ▸Patients typically experience 3 to 4 vomiting cycles per year, lasting several days each.
- ▸Many cases require multiple ER visits before correct diagnosis, costing thousands per visit.
- ▸Standard antiemetics often fail. Relief comes from hot showers and capsaicin cream.
A Code Two Decades in the Making
R11.16 · WHO · Oct 2025
For more than twenty years since CHS was first described in medical literature, patients have arrived in emergency rooms with the same brutal pattern of cyclic vomiting only to be sent home without an answer. That changes now. On October 1, 2025, the World Health Organization activated ICD-10 code R11.16 dedicated to Cannabis Hyperemesis Syndrome.
A diagnostic code might sound like a bureaucratic detail, but in clinical reality it is transformative. It allows hospitals to track CHS, insurance systems to record it, researchers to count it, and physicians to legitimize what was previously slipping through the cracks of broader vomiting categories.
According to coverage by ScienceDaily on research from the University of Washington School of Medicine, this single administrative shift could be the strongest catalyst yet for clinical recognition, public awareness, and long-overdue funding.
The ER Numbers Tell the Story
Emergency physicians have been quietly sounding the alarm for years. The pattern is unmistakable: more cannabis users, higher potency products, and a growing wave of patients arriving with severe vomiting that no medication seems to touch.
Each emergency visit can run into thousands of dollars. Many patients endure repeated rounds of bloodwork, IV fluids, imaging, and discharge with no diagnosis before someone finally connects the cyclic vomiting to chronic cannabis use.
Behind the announcement: UW Medicine's CHS research team
The clinical insight driving this update comes from Beatriz Carlini and Dr. Chris Buresh of the University of Washington School of Medicine and Seattle Children's. Their work has helped shape how emergency departments now identify, track, and ultimately treat CHS cases nationwide.
The cycles are brutal: 24 hours after a session, the nausea begins. Then come days of vomiting that no medication can stop. Patients describe huddling in scalding showers, sometimes for hours, just to find relief. For many, this had no name. Now it does.
What Researchers Still Cannot Explain
Despite the new diagnostic recognition, the underlying biology of CHS remains stubbornly mysterious. The team at UW Medicine and Seattle Children's flag several open questions that the field has yet to resolve:
- THC potency role: It is unclear whether modern high-THC cannabis is the trigger, or whether long-term cumulative exposure matters more.
- Individual vulnerability: Why some chronic users develop CHS while others do not remains unknown. Genetics is suspected but not proven.
- Why standard antiemetics fail: Conventional anti-nausea drugs often produce minimal relief in active CHS episodes, suggesting a different underlying mechanism.
- The hot-shower paradox: The reason scalding water and topical capsaicin relieve symptoms is still being investigated. The TRPV1 receptor is the leading suspect.
- Cycle frequency: Why do most patients experience exactly 3 to 4 episodes per year rather than continuous symptoms? The cyclic pattern itself is unexplained.
Recognition Is Not Acceptance
The UW Medicine researchers are clear about one thing: having a diagnostic code is not the same as having a treatment. Patients still face skepticism, stigma, and a healthcare system that often does not believe their symptoms are linked to cannabis use.
For many, the hardest part is not the vomiting. It is admitting to themselves and their doctors that the substance they have used for years for relief is now the source of their suffering. The new code helps with documentation, but the human side of CHS still depends on conversations that are difficult to have.
Diagnostic Recognition Done
ICD-10 code R11.16 activated by the WHO on October 1, 2025. Hospitals can now record CHS as a distinct diagnosis instead of generic vomiting categories.
Treatment Protocols In progress
Standardized clinical guidelines for managing CHS in the ER are still being developed. No FDA-approved treatments yet exist for the syndrome itself.
Public & Provider Acceptance Pending
Stigma persists. Many patients still face skepticism, and many physicians remain unfamiliar with CHS as a clinical entity worth taking seriously.
Cessation remains the only proven cure. Symptoms typically resolve within days to weeks of stopping cannabis use, and they almost always return when use resumes. That clinical reality has not changed. What has changed is that the chart can now say so officially.
What This Means in Practice
🏥 For ER Physicians
R11.16 should now be applied whenever CHS is the working diagnosis. Better coding leads to better data, better protocols, and faster recognition for the next patient walking through the door.
🌿 For Patients
If you have been cycling through ERs without answers, ask if CHS is on the table. The new code means your case can finally be recorded accurately and contribute to a growing evidence base.
🔬 For Researchers
Population-level CHS data is now possible for the first time. Expect a wave of incidence studies, cost analyses, and outcome research over the coming years.
📊 For Health Systems
Insurance and hospital systems can now track CHS-specific costs, readmissions, and patterns. Repeated ER visits running into the thousands per case are about to become measurable.
Frequently Asked Questions
QWhat does ICD-10 code R11.16 mean?
It is the official World Health Organization code for Cannabinoid Hyperemesis Syndrome. Activated on October 1, 2025, it allows clinicians and hospitals to formally record CHS as a distinct diagnosis instead of grouping it under generic vomiting codes.
QWhy are ER visits for CHS rising?
Researchers cannot say with certainty. Higher-potency products, broader cannabis availability, and longer-term heavy use are all suspected contributors. The new diagnostic code will help separate true incidence increases from improved recognition.
QWhy do hot showers help?
The leading theory points to the TRPV1 heat-sensitive receptor, which is closely linked to nausea pathways. Capsaicin cream, which activates the same receptor, also offers relief in many cases. The exact mechanism is still being studied.
QWhere can I read the original article?
The full article, "Why more cannabis users are landing in the ER with severe vomiting," is available on ScienceDaily, based on research from the University of Washington School of Medicine.
Join thousands sharing their CHS journey
Get real conversations, peer support, and the latest research updates inside our growing private Facebook community.
Join Our Community on FacebookSource: "Why more cannabis users are landing in the ER with severe vomiting," ScienceDaily, November 27, 2025. Research from the University of Washington School of Medicine (Beatriz Carlini, Dr. Chris Buresh).
